Concepedia

Publication | Open Access

One-year sustained efficacy of erenumab in episodic migraine

DOIFull Paper Access

61

Citations

13

References

2020

Year

Peter J. Goadsby, Uwe Reuter, Yngve Hallström, Gregor Broessner, Jo Bonner, Feng Zhang, Ian K. Wright, Denise E. Chou, Jan Klatt, Hernàn Picard,
Neurology

Abstract

Class II evidence that 52 weeks of treatment with erenumab 70 and 140 mg subcutaneously monthly results in sustained reductions in monthly migraine days and similar dose tolerability for patients with episodic migraine.

References

YearCitations

Page 1